Literature DB >> 14584822

Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies.

J Klucken1, P J McLean, E Gomez-Tortosa, M Ingelsson, Bradley T Hyman.   

Abstract

Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are neurodegenerative disorders that share progressive dementia as the common major clinical symptom. Damages to memory-related brain structures are the likely pathological correlate, and in both illnesses deposition of amyloidogenic proteins are present mainly within these limbic structures. Amyloid-beta-positive plaques and phospho-tau-positive neurofibrillary tangles are the main feature of AD and alpha-synuclein-positive Lewy bodies and Lewy neurites are found in DLB. Interestingly the associated proteins also interfere with synaptic function and synaptic plasticity. Here, we propose that the same neuronal circuits are disturbed within the hippocampal formation in AD and DLB and that in both diseases the associated proteins might lead to changes in synaptic plasticity and function. Thus both classic neuropathological changes and cellular dysfunctions might contribute to the cognitive impairments in AD and DLB.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14584822     DOI: 10.1023/a:1026061021946

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  116 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits.

Authors:  A Stéphan; S Laroche; S Davis
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

3.  Clinical and neuropathological correlates of dementia with Lewy bodies.

Authors:  E Gómez-Tortosa; M C Irizarry; T Gómez-Isla; B T Hyman
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

4.  Abnormal, ubiquitinated cortical neurites in patients with diffuse Lewy body disease.

Authors:  A Pellisé; C Roig; L I Barraquer-Bordás; I Ferrer
Journal:  Neurosci Lett       Date:  1996-03-15       Impact factor: 3.046

5.  Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus.

Authors:  Qi-Sheng Chen; Wei-Zheng Wei; Takeshi Shimahara; Cui-Wei Xie
Journal:  Neurobiol Learn Mem       Date:  2002-05       Impact factor: 2.877

6.  Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization.

Authors:  W C Colley; T C Sung; R Roll; J Jenco; S M Hammond; Y Altshuller; D Bar-Sagi; A J Morris; M A Frohman
Journal:  Curr Biol       Date:  1997-03-01       Impact factor: 10.834

7.  Identification of two distinct synucleins from human brain.

Authors:  R Jakes; M G Spillantini; M Goedert
Journal:  FEBS Lett       Date:  1994-05-23       Impact factor: 4.124

8.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

9.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

Authors:  K Uéda; H Fukushima; E Masliah; Y Xia; A Iwai; M Yoshimoto; D A Otero; J Kondo; Y Ihara; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

10.  Plasticity of hippocampal circuitry in Alzheimer's disease.

Authors:  J W Geddes; D T Monaghan; C W Cotman; I T Lott; R C Kim; H C Chui
Journal:  Science       Date:  1985-12-06       Impact factor: 47.728

View more
  8 in total

1.  Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND.

Authors:  Prashanthi Vemuri; Gyorgy Simon; Kejal Kantarci; Jennifer L Whitwell; Matthew L Senjem; Scott A Przybelski; Jeffrey L Gunter; Keith A Josephs; David S Knopman; Bradley F Boeve; Tanis J Ferman; Dennis W Dickson; Joseph E Parisi; Ronald C Petersen; Clifford R Jack
Journal:  Neuroimage       Date:  2010-12-31       Impact factor: 6.556

2.  Recent advances in the development of immunotherapies for tauopathies.

Authors:  Kiren Ubhi; Eliezer Masliah
Journal:  Exp Neurol       Date:  2010-10-21       Impact factor: 5.330

Review 3.  Epigenetics of Alzheimer's disease and frontotemporal dementia.

Authors:  Chendhore S Veerappan; Sama Sleiman; Giovanni Coppola
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

4.  Apolipoproteins in the brain: implications for neurological and psychiatric disorders.

Authors:  David A Elliott; Cyndi Shannon Weickert; Brett Garner
Journal:  Clin Lipidol       Date:  2010-08-01

Review 5.  Transgenic models of Alzheimer's disease: learning from animals.

Authors:  Tara L Spires; Bradley T Hyman
Journal:  NeuroRx       Date:  2005-07

Review 6.  Neuropathological alterations in Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Matthew P Frosch; Eliezer Masliah; Bradley T Hyman
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

7.  Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI.

Authors:  K Kantarci; R Avula; M L Senjem; A R Samikoglu; B Zhang; S D Weigand; S A Przybelski; H A Edmonson; P Vemuri; D S Knopman; T J Ferman; B F Boeve; R C Petersen; C R Jack
Journal:  Neurology       Date:  2010-06-01       Impact factor: 9.910

8.  The Impairments of α-Synuclein and Mechanistic Target of Rapamycin in Rotenone-Induced SH-SY5Y Cells and Mice Model of Parkinson's Disease.

Authors:  Mahesh Ramalingam; Yu-Jin Huh; Yun-Il Lee
Journal:  Front Neurosci       Date:  2019-09-24       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.